Macrophages take up zymosan in the absence of exogenous complement via receptors for iC3b ( 
Introduction
Various macrophage (MO)' populations bind and ingest zymosan in the absence of an exogenous opsonin (1) . Monoclonal anti-bodies directed against the functional site of the type 3 complement receptor (CR3) for iC3b-coated particles (2, 3) partially inhibit uptake ofunopsonized zymosan. Direct sugar recognition by the lectin-like mannosyl-fucosyl receptor on macrophages (MFR [4] ) has also been implicated in zymosan uptake by use of mannan as inhibitor, and additive effects of MFR and CR3 inhibitors were noted in some M) populations. We and others (5) (6) (7) have presented evidence that MO themselves produce complement components of the alternative and classical pathways. Biosynthetic labeling indicated that MO synthesize and secrete active C3 under assay conditions, and C3 convertase components, factor H and I activities, were detected in M4-conditioned medium. We therefore postulated that locally secreted complement components could opsonize targets such as zymosan for uptake via CR3. Studies by Blackwell et al. (8) have provided evidence that a similar mechanism contributes to the initial penetration of resident peritoneal mouse MO by promastigotes of Leishmania donovani, which also activate the alternative pathway of complement.
In this article we provide further evidence that the ligand iC3b is deposited on zymosan under assay conditions and examine the role of CR3 in zymosan uptake by using monoclonal antireceptor antibodies. Because polymorphonuclear leukocytes (PMN) express CR3, but are not known to secrete complement proteins, we have studied their interaction with unopsonized and iC3b-opsonized zymosan. We, like others (9, 10) , find that human PMN only take up zymosan after exogenous opsonization. Co-cultivation with MO, however, enables PMN to respond to zymosan by a vigorous respiratory burst indicating that MO complement and/or other products enable the PMN to react with zymosan particles in the absence of serum. This in vitro system indicates a novel role for the MO in interaction with PMN and initiation of the acute inflammatory response.
Methods Mice
use. 100 jsg/ml kanamycin, 50 og/ml streptomycin, and 50 ug/ml penicillin were added to media. Phosphate-buffered saline (PBS) A and B were obtained from Oxoid Ltd., Basingstoke, England. Ficoll-Paque was obtained from Pharmacia Fine Chemicals, Uppsala, Sweden. Mannan, ribonuclease B, zymosan type A, cytochrome c, superoxide dismutase, phorbol myristate acetate (PMA), and proteins used as molecular weight standards were all obtained from Sigma Chemical Co., St. Louis, MO.
Antibodies
The rat anti-mouse hybridoma Ml/70 (anti-MAC-l), used as a tissue culture supernatant at saturation or as an Fab fragment, was a kind gift from Dr. T. Springer, Harvard Medical School, Boston, MA. This antibody defines the CR3 on mouse M+, PMN, and natural killer cells (2) . MO1 (3) and OKM10 (11) 
Complement
Human C3 was prepared as previously described (14) . Factors H and I, respectively, were isolated as previously described ( 15, 16) .
Sensitized erythrocytes (E) bearing C3 fragments (C3b and iC3b) were prepared as previously described (12) . The IgM fraction from rabbit hemolysin was used to sensitize the erythrocytes (EA).
Zymosan coated with human C3b was prepared as described (17) and converted to zymosan-iC3b by incubation for 4 h at 37°C in PBS containing 10 ,g/ml factor H and 2 gg/ml factor I. Factors H and I were removed by washing in PBS. The zymosan had 14,000 C3b or iC3b sites/ particle.
Preparation ofmannan-coated and MJ/70-coated coverslips Glass coverslips were boiled in decon for 5 min and washed extensively in running tap water. Proteins were covalently coupled as described (18) . Briefly, surfaces were treated with poly-L-lysine, with glutaraldehyde, then with the Fab fragment of M1/70 at a concentration of 50 Ag/ml.
After 90 min at 20'C the unreacted glutaraldehyde was neutralized with 0.1 M glycine (pH 7.5) containing human serum albumin at 1 mg/ml. Mannan-coated coverslips were prepared as described (19) . 50 mg/ml mannan and 10 mg/ml carbodiimide hydrochloride were layered on poly-L-lysine-coated coverslips overnight at 4VC.
Deposition ofcleaved C3 on zymosan
Zymosan particles were incubated under serum-free conditions with human monocytes in the presence ofinhibitors ofuptake, recovered, washed free ofnoncovalently bound material and then stripped to remove esterbound C3 fragments. Before zymosan challenge the monocytes (-5 x 10') were cultivated for 24-36 h in medium containing 10% heatinactivated pooled human serum, washed five times, incubated for 2 h in serum-free medium to remove adsorbed proteins and incubated further for 6 h in fresh serum-free medium. Monolayers were then incubated for 30 min at 37°C with well-suspended zymosan particles, 100 per cell, in the presence of anti-CR3 monoclonal antibody and mannan. The zymosan particles were carefully collected and washed successively with 2 M NaCI, water, 1% SDS, 1% Triton X-100 in 150 mM NaCI, and finally in 6 M guanidine-HCI (pH 7.0) to remove noncovalently bound material. The material was then suspended in physiologic saline, frozen, and thawed, rewashed in 0.2 M Tris-2% SDS-8 M urea, pH 8.0, and finally incubated for 3 h at 37°C in 200 Al 50 mM diethanolamineHCl (pH 1 1.5)-100 mM NaCI-0.1% SDS. The last incubation conditions remove ester-bound C3 fragments from carbohydrate surfaces (14) . The high-pH eluate from the zymosan was radioiodinated with 125I using chloramine T to facilitate detection of protein in the eluate. The radioiodinated sample was then reduced with dithiothreitol, run on SDS polyacrylamide gels, and compared with C3 fragment standards.
Secretion ofC3 andfactor H l-d monocyte cultures were prepared as above, washed, and incubated 2 h in serum-free medium. Cells were then incubated for 12 h in methionine-free medium containing 1% bovine serum albumin and
[35S]methionine, 250 ACi/ml. Conditioned medium was collected, cleared by centrifugation, and processed as follows. 2.5 ml of supernatant containing 3.5 X 106 dpm of I'S incorporated into nondialyzable material was mixed with 1 ml of human plasma and fractionated on a 27 X 1.8-cm diam column of DEAE-cellulose equilibrated in 25 mM potassium phosphate-S mM EDTA-50 mM e-aminocaproate, pH 7.0. -40% of the radioactivity was retained on the column and this was eluted by applying a linear gradient (300 ml) of NaCl, from 0 to 0.35 M. This chromatographic procedure is a standard preparative step for C3 and factor H and the elution positions of C3 and H are well characterized (20). Cold carrier C3 and factor H in the column eluate were detected by Ouchterlony immunodiffusion using monospecific antisera. The proteins eluted in the expected positions. Portions of successive column fractions were then subjected to SDS-polyacrylamide gel electrophoresis (PAGE). The gels were treated with Autofluor (National Diagnostics, Inc., Somerville, NJ) and the "S-labeled proteins were detected by fluorography.
Assays
Uptake of 25I-zymosan. Human Mannose-specifc endocytosis. Uptake was measured using saturating amounts of trace-labeled Man-BSA as described (21) In previous studies we demonstrated the presence of native C3 in human monocyte culture supernatant by biosynthetic labeling and found low levels of factor I plus cofactor activity (? factor H) by measuring iC3b formation from C3b (1). To establish that monocytes synthesize and secrete factor H under assay conditions, we partially purified 35S-labeled factor H and C3 from 1-d cultured monocyte-conditioned medium by ion-exchange chromatography. Analysis by SDS-PAGE in both reducing and nonreducing (not shown) conditions (Fig. 1 B) indicated that both proteins were --detectable by fluorography, compared with standards. These were minor labeled components in that C3 contained <3% of the protein-bound 35S, whereas factor H contained <0.25%.
Role ofC3 in uptake ofzymosan by monocytes/Mo Previous studies (1) showed that MO and 68,000-70,000-mol wt doublet which is unresolved) and C3ba', a 108,000-mol wt cleavage product of C3b. 
CR3 and MFR are distinct receptors
Earlier studies showed that zymosan that had not been opsonized with fresh serum retained much of its biological activity (22) and that the MFR contributed to uptake of these particles (19 Fig. 2 A and legend) . The reciprocal experiment (Fig. 2 B) showed that MO-on mannan-coated coverslips expressed reduced MFR activity, but EAiC3b rosetting was similar to controls. There was no loss of MAC (Fig. 3 A and B) and ingest unopsonized and opsonized (not shown) zymosan particles. In contrast, PMN were able to bind and ingest only iC3b zymosan (Fig. 3 C and D) . Examination ofelectron micrographs showed that 22% of PMN in these sections bound or ingested iC3b zymosan after incubation for 15 min at 370C compared with 2% uptake of unop- Phase-contrast microscopy confirmed that virtually all PMN could bind or ingest iC3b-zymosan, whereas uptake of unopsonized zymosan was <10%.
Interaction of MO and PMN in response to unopsonized zymosan
In view of the foregoing observations we asked whether MO are able to opsonize zymosan particles for recognition by PMN. We designed an experiment in which Mq were exposed briefly to unopsonized zymosan under serum-free conditions, before addition of PMN which by themselves would remain unreactive to unopsonized zymosan. We assayed respiratory burst induction as a measure of the PMN response because this was suitable for analysis at the single cell level (NBT reduction) and preliminary experiments with PMN in suspension confirmed that PMN produced copious amounts ofO2 when triggered with PMA or fresh serum-treated zymosan, but not in response to unopsonized zymosan (legend to Fig. 4) . We chose 7-d cultured blood monocytes as the source of MO in these cell collaboration experiments because prolonged adhesion results in loss of respiratory burst activity to background levels ( [27, 28] Fig. 4 legend) , while the ability to bind and ingest unopsonized zymosan via the CR3 and to secrete complement (5) is substantially retained. Furthermore, experiments with freshly isolated monocytes confirmed that these cells themselves release O2 upon direct challenge with unopsonized zymosan (not shown) and were unsuitable for co-cultivation experiments. Finally, we found that isolated PMN were triggered to release 0°upon initial contact with fresh glass coverslips (27) . This could be prevented by using glass coverslips which had been coated by prior incubation in heat-inactivated human serum, as used for MO cultivation (Fig.   4 legend) (31) . Zymosan-CR3 interaction would therefore be explained by a direct interaction of a sugar shared with iC3b hence accounting for inhibition by the CR3 antibody. Our study makes this explanation unlikely in the case of monocyte/M4 interaction with zymosan.
We show that CR3 and the lectin-like MFR, which contributes to zymosan uptake by MO populations with this receptor, can be modulated independently. Modulation of complement receptors in RPM demonstrated here with anti-CR3 antibody resembles that observed with human monocytes (30) , but differs from a previous report where substratum-bound C3 failed to modulate the CR3 in RPM (18) . Successful modulation may be the result of a greater affinity of the monoclonal antibody than the ligand for the receptor. It is possible that the failure of RPM to ingest iC3b ligands is not a function of lack of mobility of the receptors, but reflects their state of nonactivation (32) . In addition, soluble mannan does not inhibit EAiC3b rosetting nor does anti-CR3 antibody inhibit MFR activity (1). Together these results make it unlikely that mannose plays a role in the MOiC3b/CR3 interaction studied here. We do not know whether the two receptors recognize distinct ligands on the zymosan surface or a complex ligand such as the mannose-rich peptidoglycan found in cell walls of yeast, parasites, and some bacteria which may act as both an acceptor surface for initial complement deposition and express exposed mannose residues. Further deposition of complement could mask fre mannosyl-residues so that uptake of serum-opsonized targets proceeds almost exclusively via CR3 (1, 8) . Finally, exogenous (30, 33) the ligands for other lymphocyte function antigens have not been identified nor can the defects be ascribed to CR3 dysfunction alone because at least three surface molecules share a com- 2374 Ezekowitz et al. mon ,8-chain which is lacking in leukocytes of these patients (36) . Further studies are also needed with monocytes from such patients.
We obtained evidence that MO can interact with zymosan to induce a respiratory burst in PMN. In co-cultivation experiments we noted that PMN are attracted to zymosan-bearing M+, aggregate, and degranulate with resultant destruction of macrophages as well as PMN, presumably a result ofthe vigorous respiratory burst. These reactions depended on the simultaneous presence of both cell types and zymosan and could be due to reaction of PMN with "opsonized" zymosan or with products ofthe M4-zymosan interaction. We have not identified the possible MO mediators involved, e.g., complement products C3a, C5a (37) , and/or leukotrienes (38) , nor have we determined whether the CR3 is able to trigger a respiratory burst in PMN (39, 40 
